Registration Options

Activity Dates: 11/27/2019 - 05/30/2020

Target Audience

This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient and disease state management in the field of psychiatric pharmacy.

Content

This recertification product consists of four clinical review articles focused on single disorders, or on one or more distinct aspects of a single psychiatric, neurologic, or substance use disorder. Authored by leading experts in the field and hosted in CPNP’s peer-reviewed journal, The Mental Health Clinician (MHC), these case-based articles will be fully referenced and offer therapeutic advice based on both evidence and longstanding clinical experience. Pearls articles focus on aspects of disease states and their pharmacotherapy that require synthesis of solutions to problems or development of practices that require judgement(s) founded on evidence, but modified or tempered by extensive clinical experience and practicalities of “real world” necessities. The articles are intended to allow you to gain greater insights into the strategies of clinical decision-making used by expert clinicians. Topics include PTSD guidelines, opioid use disorder and pregnancy, clozapine augmentation, and multiple sclerosis.

Psychopharmacology Pearls is an application-based continuing pharmacy education (CPE) activity. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. Psychopharmacology Pearls includes:

  • Four (4) articles in an electronic format.
  • Five (5) hours of ACPE credit and 5 hours of BCPP Recertification credit achieved by successfully completing the online CPNP recertification examination. ACPE credit is reported to CPE Monitor at nabp.net within 48 hours after successful completion of the examination. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed (2019 or 2020).
  • Access to the CPNP testing center with exam submission due by May 27, 2020.

Course Requirements

To satisfactorily complete the Psychopharmacology Pearls and receive 5 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the recertification education.
  2. Complete an online assessment by the deadline of May 27, 2020.
  3. Meet the minimum passing score to be determined by a panel of experts within four (4) weeks following the exam deadline.
  4. Partial credit is not available for individual topics within the learning activity; it is either all 5 hours of credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • Wait for the official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (72%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.

Faculty Information and Disclosures

Megan J. Ehret, PharmD, MS, BCPP
Nicole Hahn, PharmD, BCACP
Kristin Harter, PharmD
Shilpa Klocke, PharmD, BCPS
James L. Roerig, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

Clozapine Augmentation Strategies

  1. Interpret clinical features and treatment issues as applicable to patients with complex and/or treatment resistant schizophrenia.
  2. Evaluate risks and benefits of clozapine augmentation options and the evidence supporting them.
  3. Apply evidence and/or expert opinion to optimize clozapine augmentation treatment with a patient.
  4. Choose therapeutic management options for common or complex clinical situations involving clozapine augmentation.

Multiple Sclerosis

  1. Interpret clinical features and treatment issues as applicable to patients with complex and/or treatment resistant multiple sclerosis (MS).
  2. Evaluate risks and benefits of available treatment options for MS and the evidence supporting them.
  3. Evaluate when evidence and/or expert opinion applies to optimized treatment with a patient with MS.
  4. Choose therapeutic management options for common or complex clinical situations involving MS.

Opioid Use Disorder in Pregnancy

  1. Interpret clinical features and treatment issues as applicable to pregnant patients with Opioid Use Disorder (OUD).
  2. Evaluate risks and benefits of available treatment options for pregnant patients with OUD and the evidence supporting them.
  3. Apply evidence and/or expert opinion to optimize treatment with a pregnant patient with OUD.
  4. Choose therapeutic management options for common or complex clinical situations involving opioid use disorder in pregnancy.

Treatment of Posttraumatic Stress Disorder: Focus on Pharmacotherapy

  1. Interpret clinical features and treatment issues as applicable to patients with PTSD.
  2. Evaluate risks and benefits of available treatment options for PTSD and the evidence supporting them.
  3. Apply evidence and/or expert opinion to optimize treatment of a patient.
  4. Choose therapeutic management options for common or complex clinical situations involving PTSD.

Continuing Education Credit and Disclosures

Activity Dates: 11/27/2019 - 05/30/2020
ACPE Contact Hours: 5
ACPE Numbers: 0284-0000-19-061-H01-P (Application), 0284-0000-19-062-H01-P (Application), 0284-0000-19-063-H01-P (Application), 0284-0000-19-064-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Psychopharmacology Pearls product is an application-based program approved for 5 ACPE contact hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.

Board Certified Psychiatric Pharmacists (BCPPs) may also receive 5 hours of BCPP Recertification Credit for the Psychopharmacology Pearls upon successful completion of an online examination.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.